Article

Jeff Cross Article Analyzes ‘Pay-for-Delay’ Case Before Supreme Court

The decision in the Supreme Court case of Federal Trade Commission v. Actavis has a potential to shape the contours of brand-name infringement litigation against generic drug manufacturers that could also alter the framework of the Hatch-Waxman Act. In “Is the Hatch-Waxman Act Flawed and Should the Supreme Court Fix It?,” published May 14, 2013, by Becker’s Hospital Review, Jeffery M. Cross reviews the case and possible outcomes.

Read the article, Is the Hatch-Waxman Act Flawed and Should the Supreme Court Fix It?